Navigation Links
Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting
Date:2/27/2012

to this new mu-opioid analgesic molecule is that it does not rely on a formulation to decrease its abuse liability. With a ten-fold slower entry into the brain as compared to oxycodone, NKTR-181 avoids the rush into the brain associated with euphoria.  Adding to our excitement is the data that shows the peripheral analgesic and anti-hyperalgesic effects of NKTR-181 in multiple pain models. We will seek to capitalize on the properties of this unique molecule as we advance NKTR-181 into Phase 2 development this year."

In a separate presentation of preclinical data at the AAPM Meeting, NKTR-181 resulted in less sedation and abuse liability as compared to oxycodone in multiple animal models across a wide range of doses.  As predicted from its molecular design, NKTR-181 has a reduced rate of entry into the brain in rodents.  This feature contributed to a 30-fold shift in the dose-response for abuse liability and a 10-fold shift in the dose response for sedation relative to oxycodone.

Chronic pain conditions, such as osteoarthritis, back pain and cancer pain, affect at least 126 million adults in the U.S. annually and contribute to over $100 billion a year in lost productivity.(2) 

About the NKTR-181 Phase 1 Multiple Ascending Dose Study

This Phase 1, double-blind, randomized, placebo-controlled, ascending multiple dose study of NKTR-181 was conducted in the U.S. at Lifetree Clinical Research. The study enrolled a total of 60 healthy subjects over an eight-day treatment period.  Four dose cohorts were evaluated with 15 subjects in each dose cohort (100 mg, 200 mg, 300 mg, 400 mg).  Subjects in each cohort received oral twice-daily doses of NKTR-181 (n=12) in aqueous solution or placebo (n=3) following an overnight fast.  Pharmacokinetics were determined through serial blood samples. Serial opioid pharmacodynamic tests included the cold-pressor test (CPT) and a UVB injury model to assess both central
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
2. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
3. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
7. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
8. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... BRUNSWICK, N.J., March 19, 2012  Johnson & Johnson ... and other interested parties on Monday, March 26th ... with the American College of Cardiology (ACC) Annual ... Phase 3 results of the EINSTEIN-PE study in ...
... N.J. and SYDNEY, March 19, 2012 QRxPharma Limited (ASX: ... and Option Agreement (LOA) with Actavis, Inc. which finalised the ... US acute pain marketplace.  The LOA completion follows a 20 ... secured by a US$6 million non-refundable upfront signing fee to ...
Cached Medicine Technology:QRxPharma Signs License and Option Agreement with Actavis 2QRxPharma Signs License and Option Agreement with Actavis 3QRxPharma Signs License and Option Agreement with Actavis 4
(Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... heart drugs may help counter the effect, researchers say ... to hasten the progression of aggressive or advanced melanoma ... slow the disease and improve the quality of patients, ... In laboratory tests, the researchers exposed samples of three ...
... There are approximately 7.1 million injury-related emergency department (ED) ... States annually, according to the Centers for Disease Control ... universities, including the University of Missouri, found that young ... to have been reported to Child Protective Services (CPS) ...
... Total Revenue Increased 15%; Online Ad Revenue Increased ... Monthly Users and 1.3 Billion Quarterly Page ViewsNEW ... WBMD ) today announced financial results ... fourth quarter results confirm WebMD,s market leadership in ...
... HLTH Corporation (Nasdaq: HLTH ... ended December 31, 2008. "We are pleased with ... Wygod, Chairman and Acting Chief Executive Officer of HLTH ... offer which reduced its shares outstanding by 45% and ...
... TELK ) announced that its year-end conference call ... 4:30 p.m. Eastern time (1:30 p.m.,Pacific time) following the release ... quarter and year ended December 31, 2008. , ... website at, http://www.telik.com or by telephone at 800-288-8974 or ...
... greatest risk seem to know the least, survey finds, , , THURSDAY, ... five warning signs of a stroke and what to do if ... according to new research. , Older people and those who,ve already ... able to recognize the symptoms of a stroke and know to ...
Cached Medicine News:Health News:Stress May Speed Melanoma Progression 2Health News:Researchers recommend increased physician awareness to reduce injuries and neglect in children 2Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:HLTH Corporation Announces Fourth Quarter Financial Results 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 3Health News:HLTH Corporation Announces Fourth Quarter Financial Results 4Health News:HLTH Corporation Announces Fourth Quarter Financial Results 5Health News:HLTH Corporation Announces Fourth Quarter Financial Results 6Health News:HLTH Corporation Announces Fourth Quarter Financial Results 7Health News:HLTH Corporation Announces Fourth Quarter Financial Results 8Health News:HLTH Corporation Announces Fourth Quarter Financial Results 9Health News:HLTH Corporation Announces Fourth Quarter Financial Results 10Health News:HLTH Corporation Announces Fourth Quarter Financial Results 11Health News:HLTH Corporation Announces Fourth Quarter Financial Results 12Health News:HLTH Corporation Announces Fourth Quarter Financial Results 13Health News:HLTH Corporation Announces Fourth Quarter Financial Results 14Health News:HLTH Corporation Announces Fourth Quarter Financial Results 15Health News:HLTH Corporation Announces Fourth Quarter Financial Results 16
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... BioControl multichannel has the ... the single channel model.The ... allseven multichannel and five ... modules. Both pipettes have ...
Medicine Products: